CLLS Cellectis Biotherapeutics Company Net Income

Corporate emblem and logo of Cellectis S.A. (CLLS)

The development of Cellectis S.A. (CLLS) relies on the safety of genetic modifications during trials and stable funding, while royalty inflows maintain liquidity at -0.07. Cellectis S.A. (CLLS) also complies with environmental regulations by implementing energy-efficient solutions and emission filtration in its laboratories. This price chart on the GURU.Markets platform reflects the price action of this developer of innovative oncology treatment methods.

CLLS cellectis.com: Net Income in the range 07/04/2022 - 10/29/2026

Financial and market metric breakdowns for cellectis.com (CLLS)

- share price and consensus valuation forecast:
Price Chart Cellectis|CLLS - Price Target Chart
- market capitalization data:
Market Value CLLS|CLLS - Enterprise Value
- balance sheet equity data:
Book Value of One Share Cellectis S.A.|CLLS - Company Net Assets|Market-to-Book Ratio cellectis.com|CLLS - Cumulative Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Cellectis S.A.|CLLS - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Cellectis|CLLS - Company Aggregate Debts|Debts to Book Value CLLS|CLLS - Company Long-Term Debt|Company Short-Term Debt Cellectis S.A.|Quick Liquidity cellectis.com
- business earnings and investment ratios data:
CLLS - Net Income
Fundamental valuation:CLLS Cellectis Biotherapeutics
Manufactured products of Cellectis SA

Cellectis S.A. (CLLS) holds fundamental patents for CAR-T technologies, creating potential for long-term royalties. The economic impact of this intellectual property is reflected in the daily net earnings trend of the business. This metric captures the final financial result, eliminating the time lag associated with quarterly reporting. It measures the company's real ability to generate cash flow. By analyzing the current net profit of Cellectis S.A. (CLLS), an investor can identify hidden risks of revenue stagnation.

Main competitors

LEGN (Legend Biotech Corp.) - Company Net Income|Company Net Income Sana Biotechnology|Company Net Income autolus.com AUTL|Net Profit ALLO|Selecta Biosciences (RNAC) - Annual Net Income|Caribou Bio - Net Income|Instil Bio Inc (TIL) - Company Net Income|GNTA: Net Income|Final Profit IPSC (Century Therapeutics)|JSPR: Net Profit|Net Income Senti Biosciences|ADAP (Adaptimmune Therapeutics plc) - Net Profit|Company Net Income CERo Therapeutics Holdings Inc. CERO|Company Net Income Alaunos Therapeutics (TCRT)|Company Net Income ACHL (achillestx.com)|Company Net Income CARGO Therapeutics, Inc. CRGX|Poseida Therapeutics Inc - Company Net Income|TSVT: Net Income|Final Profit GRCL (Gracell)